IceCure Medical (NASDAQ:ICCM - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 27th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The company had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.07 million. IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. On average, analysts expect IceCure Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
IceCure Medical Stock Down 1.4%
ICCM stock opened at $1.03 on Tuesday. The company has a market cap of $56.89 million, a PE ratio of -3.53 and a beta of 0.41. The business has a 50-day simple moving average of $1.16 and a 200 day simple moving average of $1.12. IceCure Medical has a 52 week low of $0.48 and a 52 week high of $1.66. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "buy" rating and issued a $2.50 target price on shares of IceCure Medical in a report on Friday, March 28th.
Get Our Latest Analysis on IceCure Medical
About IceCure Medical
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
